AIMSS评分对无症状脑膜瘤生长预测的验证研究
结果共纳入46例患者的69个无症状脑膜瘤,低危组31个、中危组34个、高危组4个;结论认为AIMSS评分可有效评估无症状脑膜瘤快速生长风险,尤其有助于区分低危与中危病变。
要点
- AIMSS评分可用于预估无症状脑膜瘤的快速生长风险。
- 低危组未见快速生长,中危组12%,高危组25%。
核心结论
- AIMSS评分是评估无症状脑膜瘤快速生长风险的有效工具。
- 该评分尤其有助于区分低危与中危脑膜瘤,可辅助调整影像学随访周期。
主要发现
- 共纳入46例患者的69个无症状脑膜瘤,低危组31个、中危组34个、高危组4个。
- 快速生长(>2cm³/年)比例:低危组0%,中危组12%,高危组25%。
关键数值与推荐
- AIMSS评分分组:低危0-2分,中危3-6分,高危7-11分。
- 快速生长定义为年生长速率>2cm³/年。
临床怎么用
- 对无症状脑膜瘤可计算AIMSS评分以分层快速生长风险。
- 低危与中危患者可依据评分调整影像学和临床随访间隔。
局限性
- 高危组样本量较小(仅4个病灶),可能影响该组预测能力的评估。
- 原文提出加入更多已知快速生长风险因素或可改善对高危组的预测能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of asymptomatic meningiomas represents a challenge due to the absence of a solid consensus on which is the best management strategy. There are various known factors predicting meningiomas growth risk. However, the Asian Intracranial Meningioma Scoring System (AIMSS) is the only described score to quantify such risk thus emerging as a potential tool for management decisions. This study aims to validate this score on our series of asymptomatic meningiomas. METHOD: We performed a retrospective review of asymptomatic meningiomas diagnosed at our institution between January 2008 and October 2016 and followed by an annual cerebral Magnetic Resonance Imaging (MRI). For each lesion, the AIMSS score was calculated thus classifying them in low (0-2), intermediate (3-6) or high risk (7-11) of rapid growth (>2cm3/year). We investigated the correlation between the expected Average Growth Rate (AGR) according to the score and the one obtained in our study. The mean growth velocity over the different risk groups was also compared. RESULTS: Overall, 69 asymptomatic meningiomas found incidentally in 46 patients were included in the study; 31 were assigned to the low-risk group, 34 to the intermediate-risk group and 4 to the high-risk group. Attending to the AGR, 0% showed rapid growth in the low-risk group, 12% in the intermediate-risk group, and 25% in the high-risk group. The mean growth velocity showed a significant difference over the different risk groups (p < 0,001). CONCLUSIONS: According to our finding, the AIMSS score is a valid tool to estimate the risk of rapid growth of asymptomatic meningiomas. It is especially useful distinguishing between low- and intermediate-risk meningiomas. This feature would allow physicians to adjust the periodicity of radiological and clinical controls. Adding more known risk factors of rapid growth to the score might improve its predictive capabilities with the high-risk group.
引用
- Brugada-Bellsolà F, Teixidor Rodríguez P, Rodríguez-Hernández A, et al. Growth prediction in asymptomatic meningiomas: the utility of the AIMSS score. Acta Neurochir (Wien). 2019. PMID: 31489530. doi:10.1007/s00701-019-04056-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。